Cardiorenal Syndrome Type 2: From Diagnosis To ...

Thoracoabdominal Aortic Aneurysm Repair: Curren...

Adding Multiple Risk Factors Improves Framingha...

Transcatheter Closure Of Secundum Atrial Septal...

Xantus: Rationale And Design Of A Noninterventi...

0 votes
Lcz696 An Innovation For Heart Failure
Author: Herbert Lima Mendes, Italo Cordeiro Moreira, Gabriel Pereira Bernardo, José Angelo Araújo Sampaio, Vanessa Lacerda Araújo, Rodrigo Amorim Quesado, Ticiane Ponciano De Oliveira Lima, Priscilla Lucena De Figueiredo, José Nunes De Alencar Neto, Ange
Publisher: Internet Medical Publishing
4 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
DOI: 10.3823/1861
Follow this publisher

Share this publication:


Despite having obtained drugs that help in the disease development control, have been sought new alternatives for better management of these individuals. The LCZ696, a neprilysin inhibitor (sacubitril) associated with an ARB (valsartan) has shown signifiant improvements in patients' morbidity and mortality, which puts it as a good and interesting option for the treatment of heart failure.

About the publisher:

iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.

Select a payment method